key: cord-0716582-46ztqs1c
authors: Muramatsu, Hiromi; Lam, Kieu; Bajusz, Csaba; Laczkó, Dorottya; Karikó, Katalin; Schreiner, Petra; Martin, Alan; Lutwyche, Peter; Heyes, James; Pardi, Norbert
title: Lyophilization provides long-term stability for a lipid nanoparticle-formulated nucleoside-modified mRNA vaccine
date: 2022-02-04
journal: Mol Ther
DOI: 10.1016/j.ymthe.2022.02.001
sha: 46594ee5a202621515d925f74039d5c45a055667
doc_id: 716582
cord_uid: 46ztqs1c

Lipid nanoparticle (LNP)-formulated nucleoside-modified mRNA vaccines proved to be very successful in the fight against the COVID-19 pandemic. They are effective, safe, and can be produced in large quantities. However, the long-term storage of mRNA-LNP vaccines without freezing is still a challenge. Here, we demonstrate that nucleoside-modified mRNA-LNPs can be lyophilized, and the physicochemical properties of the lyophilized material do not significantly change for 12 weeks after storage at room temperature and for at least 24 weeks after storage at 4oC. Importantly, we show in comparative mouse studies that lyophilized firefly luciferase-encoding mRNA-LNPs maintain their high expression and no decrease in the immunogenicity of a lyophilized influenza virus hemagglutinin-encoding mRNA-LNP vaccine was observed after 12 weeks of storage at room temperature, or for at least 24 weeks after storage at 4oC. Our studies offer a potential solution to overcome the long-term storage-related limitations of nucleoside-modified mRNA-LNP vaccines.

Lipid nanoparticle (LNP)-formulated nucleoside-modified messenger RNA (mRNA) vaccines developed by Moderna and Pfizer-BioNTech demonstrated safety and very high (>90%) efficacy and are at the forefront of the battle against the COVID-19 pandemic. [1] [2] [3] Currently, the most critical limitation of this novel vaccine platform is the requirement of a special cold-chain system for long-term storage. While most conventional vaccines can be stored at 2-8 o C in a refrigerator for at least 6 months, mRNA-LNP vaccines need to be stored frozen presenting a considerable obstacle to vaccine distribution in countries with poor infrastructure. Lyophilization (freeze-drying) is commonly used in the pharmaceutical industry to increase the stability and shelf life of various products by removing the water from drug formulations. 4, 5 In a freeze-dried form, mRNA-LNP vaccines could be conveniently shipped worldwide without the need of cooling or freezing.

However, lyophilization of LNPs is less than straightforward. While the process is readily applied to true solutions, LNPs are much more complex; carefully assembled using well-defined processes, 6 these nanostructured particles are made from specific types of lipids at certain ratios. 7 Physicochemical parameters such as particle size, polydispersity and proper payload encapsulation are critical to biological performance, and must be retained during the lyophilization process itself, and subsequent storage.

Careful selection of lyophilization buffers, cycle process parameters and temperatures is of utmost importance to ensure they are preserved.

Recent studies have shown that LNPs containing small interfering (si)RNA or mRNA can be successfully lyophilized. [8] [9] [10] Tekmira Pharmaceuticals developed an LNP J o u r n a l P r e -p r o o f for treatment of Zaire Ebola virus (ZEBOV) infection, containing siRNA targeting VP24, VP35 and L polymerase proteins. 11, 12 After demonstrating complete protection of nonhuman primates (NHP) in an otherwise lethal model of ZEBOV, a reformulated, lyophilized version (TKM-100802) was assessed in a phase 1 clinical trial in 2014 (NCT02041715). 13 While Tekmira had reported equivalent efficacy with the wet and lyophilized formats of their siRNA-LNP, not all studies have had the same conclusion.

Ball et al found that siRNA-LNPs can be lyophilized but they show significantly lower efficacy (gene silencing in cell culture) after reconstitution with water. 8 Two recent studies demonstrated that the mRNA-LNP platform can also be lyophilized. 9 ,10 Zhao et al generated lyophilized firefly luciferase-encoding mRNA-LNPs and demonstrated that the reconstituted material maintains the mRNA expression efficiency in mice as observed with in vivo bioluminescence imaging studies. 9 Hong et al developed a lyophilized SARS-CoV-2 mRNA-LNP vaccine formulation and showed that the reconstituted vaccine can induce strong immune responses in mice. 10 Importantly, none of these publications provide information on the stability of lyophilized mRNA-LNP formulations over time.

Here, we describe a very efficient lyophilization procedure that can be used to produce nucleoside-modified mRNA-LNPs as freeze-dried cake. Lyophilized mRNA-LNPs were generated and stored at -80 o C, -20 o C, 4 o C, 25 o C (room temperature) and 42 o C for 4, 12 or 24 weeks. We demonstrate that the physicochemical properties of mRNA-LNPs do not significantly change after storage at room temperature for 12 weeks, or 4 o C for at least 24 weeks, and then reconstitution with water. Using the same storage conditions, we show that firefly luciferase-encoding mRNA-LNPs do not lose their high translatability as measured by in vivo bioluminescence imaging studies in mice. Most J o u r n a l P r e -p r o o f importantly, we demonstrate in comparative mouse immunization studies that a nucleoside-modified mRNA-LNP influenza virus vaccine does not lose potency after 12 weeks of storage at room temperature or for at least 24 weeks at 4 o C as a lyophilized product. We believe that this report represents a major advancement in the field of mRNA-LNP vaccine development as it offers a potential solution for the suboptimal long-term storage temperature requirements of these potent new generation vaccines.

Lipid nanoparticles comprised of the ionizable lipid (6Z,16Z)-12-((Z)-dec-4-en-1yl)docosa-6,16-dien-11-yl 5-(dimethylamino)pentanoate, 1,2-distearoyl-sn-glycero-3phosphocholine (DSPC), cholesterol, and PEG2000-C-DMA at a molar ratio of 50:10:38.5:1.5 were formulated using a modified version of our proprietary T-mixer manufacturing process [US 9,005,654]. This involves mixing lipids dissolved in ethanol with a low-pH, aqueous solution of nucleic acid in a T-shaped mixing chamber. Lipid nanoparticles form spontaneously as ethanol concentration drops below that required to support lipid solubility. Particles are then rapidly stabilized by further dilution with aqueous buffer in the collection reservoir. The process is robust, highly scalable and has been used to encapsulate a variety of nucleic acids, including siRNA and mRNA. 6, 12, 14 Here, we separately encapsulated two different mRNAs encoding either firefly luciferase (Luc) or hemagglutinin from the A/Puerto Rico/8/1934 influenza virus strain (PR8 HA) in LNP, subsequently exchanging the carrier buffer to 5 mM Tris pH 8, containing 10% sucrose J o u r n a l P r e -p r o o f 6 and 10% maltose (w/v). LNP formulations were then freeze-dried using a VirTis Genesis Pilot Lyophilizer . The lyophilization cycle consisted of a freezing step at -45 o C, a primary   drying step at -25 o C and 20 mTorr, and a secondary drying step at 30 o C and 20 mTorr. At the completion of the cycle, samples were brought to atmospheric pressure, backfilled with ultrapure nitrogen gas, stoppered, then transferred to various storage temperatures (-80 o C, -20 o C, 4 o C, 25 o C, 42 o C) for stability monitoring. All samples were noted to have a dense, white, freeze-dried cake structure. Aliquots from the same batch of mRNA-LNP were stored frozen at -80 o C and served as a benchmark control in this evaluation.

At set timepoints (0, 4, 12, and 24 weeks after production), lyophilized mRNA-LNPs were removed from storage. The lyophilized vials were inspected for cake appearance, which can be indicative of physicochemical changes that may impact product quality and biological performance. 15 All lyophilized vials contained a uniform and elegant cake ( Figure S1 ), showing no signs of cake collapse, shrinkage, or cracked texture. This cake was quickly reconstituted by addition of nuclease-free water to a target concentration of 0.5 mg/mL total mRNA. After addition of water, vials were gently inverted several times and quickly acquired a clear, opalescent appearance with no visible solids ( Figure S2 ).

We had previously assessed the stability of this LNP composition in a frozen format. These studies found no change in key quality attributes when stored for 1 year at -80 o C (Table S1 ). To generate a similar dataset with this set of lyophilized products, we first analyzed the properties of the wet Luc and PR8 HA mRNA-LNPs before and after J o u r n a l P r e -p r o o f freeze-thaw, and post-reconstitution of the lyophilized samples at release, marking the week 0 timepoint (Table S2) . Hereafter, the frozen and reconstituted samples in the time course study were analyzed using stability-indicating assays for total RNA content, mRNA purity, % RNA encapsulation, lipid identity, lipid content, mean particle size, and polydispersity.

We utilized dynamic light scattering (DLS) to characterize particle size and polydispersity (size distribution). Frozen LNP stored at -80 o C showed no particle size change over time ( Figure 1A) . Similarly, lyophilized LNP stored at 4 o C and below also maintained particle size integrity for at least 24 weeks after production. In contrast, lyophilized samples stored at elevated temperatures reported an increase in z-average diameter. Interestingly, despite exhibiting size growth, these samples maintained a narrow size distribution, where polydispersity index was < 0.10 ( Figure 1B) . We also noted that particle size increase reached a plateau following 4-week storage of lyophilized LNP at 42 o C.

Encapsulation efficiency was measured by the RiboGreen assay, which relies on a dye that fluoresces upon binding to single-stranded mRNA. Dye accessibility is low with intact LNPs, so only unencapsulated mRNA is detected. To determine the total mRNA concentration, entrapped mRNA is released by addition of a detergent (Triton X-100) to lyse the LNP. The ratio of fluorescence intensity before and after addition of Triton allows calculation of the proportion of encapsulated mRNA payload, typically > 90% in stable formulations. There was no significant change in encapsulation efficiency of mRNA-LNPs stored under most conditions, including lyophilized mRNA-LNP stored for 24 weeks at room temperature ( Figure 1C ). Only at 42 o C storage, the lyophilized PR8 HA mRNA-LNP J o u r n a l P r e -p r o o f product showed a steady decline in encapsulation efficiency after the first 12 weeks, followed by an increase between 12 and 24 weeks. While there is no binding interference of RiboGreen with unencapsulated single nucleotides, the increased encapsulation observed at 24 weeks may be due to binding of the dye to degraded segments of the mRNA payload. This hypothesis correlates well to the measured total mRNA concentration. Lyophilized product stored at 42 o C reported a steady decline in total mRNA content over time, including the 24-week timepoint. All other storage formats and conditions reported no significant change in total mRNA concentration over this time period ( Figure 1D ).

The integrity of nucleoside-modified mRNA-LNPs was assessed by capillary electrophoresis. No notable changes in mRNA integrity were observed for the -80 o C frozen product, as well as the lyophilized product stored at either -20 o C or -80 o C, for at least 24 weeks ( Figure 1E , Figure S3 ). Above subzero temperatures, mRNA chemical degradation was observed in a temperature-dependent manner. For lyophilized mRNA-LNP stored at 4°C for 24 weeks, there was an approximate 10 -15% decrease in RNA integrity. Meanwhile, samples stored at 25 o C reported approximately 30% reduction in mRNA integrity. It is important to note that no further mRNA degradation was observed for the PR8 HA mRNA-LNPs between 12 and 24 weeks for both 4 o C and 25°C storage conditions. The lyophilized samples stored at 42 o C reported the greatest loss of mRNA integrity (approximately 70%).

All four lipid components were analyzed by Ultra High Performance Liquid Chromatography (UHPLC) and are stable for at least 24 weeks, regardless of the LNP format and storage temperature ( Figure S4 , Figure S5 ). Importantly, the lipid composition To further demonstrate the benefits of lyophilization, we conducted a comparative study between non-lyophilized and lyophilized samples stored at different temperatures for 4 weeks. Since the datasets for Luc and PR8 HA mRNA-LNPs were very comparable in the main stability arm, we conducted this direct comparison with Luc mRNA-LNP only.

In this short-term stability study, non-lyophilized LNP was stored as a wet formulation at (Table S3) .

Additionally, an in-use stability study was performed at room temperature with the Luc mRNA-LNP. Both frozen and lyophilized samples were removed from -80 o C storage, thawed and reconstituted (if applicable), then held at 25 o C for up to 24 hours. All attributes were comparable to the samples at time 0 (Table 1) . These results support in-use stability of both -80 o C frozen and lyophilized/reconstituted samples for at least 24 hours at 25 o C, which exceeds the current in-use stability instructions of approved mRNA-based COVID-

The translatability of Luc mRNA-LNPs were evaluated in mice by in vivo imaging studies.

As most vaccines are given intramuscularly (IM) or intradermally (ID), mRNA-LNPs were tested after IM and ID injections (Figure 2 ; Figures S6 and S7 ). Animals were injected IM with Luc mRNA-LNPs and protein production from the frozen and reconstituted lyophilized products stored for 0, 4 and 24 weeks were examined (Figure 2A ; Figure S6 ).

Lyophilization results in some decrease in activity of Luc mRNA-LNPs compared to the frozen formulations ( was added to the PR8 HA study protocol, to provide more detailed information. Similar to previous experiments, frozen mRNA-LNPs served as a benchmark control in this evaluation. When administered IM, no significant difference between the activity of frozen and freshly reconstituted lyophilized formulations were found ( Figure 3A ). Despite some decrease in mRNA integrity ( Figure 1D ), the immunogenicity of the lyophilized vaccines did not decrease after 12 weeks of storage at room temperature ( Figures 3B and 3C) .

Impressively, no drop in PR8 HAI activity and only a modest decrease was found after 24 weeks of storage at 4 o C or at room temperature, respectively ( Figure 3D ). In agreement with previous measurements, storing PR8 HA mRNA-LNPs at 42 o C resulted in a significant drop in activity by week 4 ( Figure 3B ), a substantial further decrease by week

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has motivated a global effort to develop a protective vaccine. Messenger RNA is an attractive vaccine modality, owing to its flexibility in antigen design and the speed of development and production. However, effective mRNA vaccines require both efficient mRNA delivery to cells and a high level of antigen expression to induce robust immune responses coupled with durable protective immunity. Specialized delivery technologies such as LNP, are required to realize their full potential. Despite real world evidence demonstrating the advantages of this promising novel platform, the instability of mRNA-LNP vaccines and the need for frozen storage remain major limitations. Here, we investigated lyophilization to address long-term pharmaceutical stability of these formulations.

Lyophilization, or freeze-drying, is one of the most common methods for long-term preservation of drug products, including colloidal nanoparticle suspensions. 4, 5 Physical instability can be characterized as aggregation or fusion of the nanoparticles, manifesting as an increase in particle size or polydispersity. Chemical instability is most often observed as degradation of the mRNA payload and/or lipid components. Either form of instability would pose challenges for storage in aqueous buffer as a wet formulation.

Extrinsic parameters, such as storage buffer pH and temperature, may further impact stability. As a result, lyophilization buffers, cycle times, and temperature are important parameters for preserving the physicochemical parameters of LNP.

Nucleoside-modified mRNA-LNPs were produced as a freeze-dried cake through lyophilization. For a quick assessment on the success of this process, macroscopic J o u r n a l P r e -p r o o f analysis was performed by visually inspecting the lyophilized product for cake appearance. Observations such as cake collapse, shrinkage, or cracked texture, may indicate potential changes in LNP characteristics. The lyophilized vials in this study presented a uniform and elegant cake that was rapidly restored to its original state after resuspension in nuclease-free water. The reconstituted samples acquired a clear, opalescent appearance with no visible solids.

Particle size is an important stability parameter, and can influence pharmacokinetics, distribution, safety, and efficacy. Frozen and lyophilized LNP stored at 4 o C (and lower temperatures) reported particle size stability for at least 24 weeks. Room temperature storage of the lyophilized vials provided at least 4 to 12 weeks of particle size stability. Under the most accelerated storage condition of 42 o C, the lyophilized product exhibited a large increase in particle size between 0 and 4 weeks, but remained stable for at least 24 weeks. Under these conditions, the maximum particle diameter was less than 150 nm. Importantly, this particle size is still within the range where LNP has been reported to elicit robust immune responses in animals, including non-human primates. 17 As mRNA is an active drug substance, contributing to the immunogenicity and efficacy of the successful mRNA-LNP vaccines, it is important to monitor its encapsulation efficiency, integrity, and content. With intact and stable LNPs, the encapsulation efficiency of mRNA payload is typically > 90%. Here, we found no change in this parameter under most storage conditions, including lyophilized mRNA-LNP stored for 24 weeks at room temperature. Moreover, all lyophilized LNP stored at room temperature and below reported no change in total mRNA concentration during the course of this study. While J o u r n a l P r e -p r o o f currently there are no published criteria on the acceptable limits of RNA integrity and its threshold on vaccine efficacy, it is critical to prevent mRNA degradation to ensure biological performance. RNA integrity represents the most temperature-sensitive, stability-limiting parameter. Remarkably, no notable changes in Luc and PR8 HA mRNA integrity were observed for LNP products stored at subzero temperatures for at least 24 weeks. mRNA chemical degradation was observed in a temperature-dependent manner, resulting in an approximate 10 -15% decrease in RNA integrity for lyophilized mRNA-LNP stored for 24 weeks at 4 o C and an approximate 30% reduction in RNA integrity for lyophilized mRNA-LNP stored for 24 weeks at room temperature. Impressively, the 4 o C lyophilized samples still maintained the same in vivo potency as the frozen samples.

Meanwhile, only slight decreases in immunogenicity were observed with lyophilized PR8 HA mRNA-LNP samples stored at room temperature for 24 weeks. It is important to note that no further mRNA degradation was observed for the PR8 HA mRNA-LNPs between 12 and 24 weeks for both 4 o C and room temperature storage conditions. The lyophilized samples stored at 42 o C reported the greatest loss of mRNA integrity (approximately 70%); however, this degree of degradation did not completely abrogate in vivo potency.

As each lipid component in the LNP has specific functions during particle formation, stabilization, and biological performance, it is critical to maintain stability of lipid components to ensure a pharmacologically active drug product. The amine group of the ionizable lipid is positively charged at acidic pH, promoting encapsulation of the negatively charged mRNA payload during particle formation. Following cellular uptake of the LNP, it further drives endosomal fusion and cytoplasmic release of payload. The polyethylene glycol (PEG)-conjugated lipid controls particle size during formation and prevents particle aggregation by sterically stabilizing the LNP. Distearoylphosphatidylcholine (DSPC) and cholesterol are often referred to as structural lipids with concentrations chosen to optimize particle size, encapsulation, and stability. In aggregate, the LNP serves to protect the delicate RNA molecule from serum nucleases during transition to target cells and promotes uptake and delivery. All four lipids maintained their integrity under all storage conditions tested in this study. These trends are impressive as some ionizable lipids and DSPC are susceptible to temperature and pH-dependent hydrolysis, which was not observed here. 18 All frozen and lyophilized LNPs maintained the target molar ratio of 1.5: 50: 38.5: 10 (PEG lipid: ionizable lipid: cholesterol: DSPC).

Overall, these results are very encouraging as other groups that evaluated stability of lipid-based nanoparticles encapsulating Luc mRNA reported significantly lower bioluminescence signal in vivo after storing the lyophilized product for 1 week at -80 o C. 9 Although the presence of cryoprotectant stabilized particle size, they speculated that the nanostructure of these mRNA formulations was altered during the lyophilization and reconstitution process, thereby affecting their delivery efficiency in vivo. In our studies, we were able to maintain key physicochemical attributes of our lyophilized mRNA-LNP product and demonstrate high in vivo translation. 

The investigators faithfully adhered to the "Guide for the Care and Use of Laboratory 

Eight week-old female BALB/c mice (Charles River Laboratories) were utilized for this study. Lyophilized mRNA-LNPs were reconstituted by addition of nuclease-free water to a target concentration of 0.5 mg/mL total mRNA. Reconstituted mRNA-LNPs were filtered by using a 13mm 0.2 µm syringe filter (Pall Acrodisc®). mRNA-LNPs were diluted with sterile PBS (Corning) and administered via the intramuscular or intradermal routes using a 3/10cc 29½G insulin syringe (Covidien) and 40 µL or 30 µL injection volumes, respectively.

Mice were isoflurane-anesthetized and blood was collected through the retro-orbital route.

Serum was separated from blood by centrifugation at 10 000 g for 5 min. Separated serum was stored at -20 o C until used.

Bioluminescence imaging was performed with an IVIS Spectrum imaging system (Caliper Life Sciences). Mice were administered D-luciferin (Regis Technologies) at a dose of 150 mg/kg intraperitoneally. Mice were anesthetized after receiving D-luciferin in a chamber with 3% isoflurane (Piramal Healthcare Limited) and placed on the imaging platform while being maintained on 2% isoflurane via a nose cone. Mice were imaged at 5 min post administration of D-luciferin using an exposure time of 5-60 seconds to ensure that the signal acquired was within effective detection range (above noise levels and below CCD saturation limit). Bioluminescence values were quantified by measuring photon flux (photons/second) in the region of interest where bioluminescence signal emanated using the Living IMAGE Software provided by Caliper.

12.5 μL of turkey erythrocyte solution (Lampire) -washed twice in phosphate buffered saline and diluted to a final concentration of 2% (v/v) -was added, and gently mixed with the sera-virus solution (final volume of 125 µL). Samples were incubated for 45 min at room temperature, after which the plates were turned on the side for one minute, then scanned on a regular office scanner. HAI titers were determined as the highest dilution of the sample that inhibited four agglutinating doses of the influenza virus. Inhibition of agglutination was observed as the blood forming a "tear drop" shape.

Data were collected and expressed as average ± standard error of the mean (SEM). 

Norbert Pardi is named on a patent describing the use of nucleoside-modified mRNA in lipid nanoparticles as a vaccine platform. He has disclosed those interests fully to the University of Pennsylvania, and he has in place an approved plan for managing any potential conflicts arising from licensing of that patent. Katalin Karikó is an employee of BioNTech. 

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

mRNA Vaccines in the COVID-19 Pandemic and Beyond

An overview of liposome lyophilization and its future potential

Recent advances and further challenges in lyophilization

A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA

Rational design of cationic lipids for siRNA delivery

Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization

Long-term storage of lipid-like nanoparticles for mRNA delivery

An mRNA vaccine against SARS-CoV-2: Lyophilized, liposome-based vaccine candidate EG-COVID induces high levels of virus neutralizing antibodies

Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study

Progress in the Development of Lipid Nanoparticle-RNA Therapeutics

Nanomaterial Delivery Systems for mRNA Vaccines

Lyophilized Drug Product Cake Appearance: What Is Acceptable?

Addressing the Cold Reality of mRNA Vaccine Stability

Impact of lipid nanoparticle size on mRNA vaccine immunogenicity

mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability

Lipid nanoparticles for mRNA delivery

Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice

A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA

Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery